Skip to main content
. 2017 Aug 10;8(59):100734–100745. doi: 10.18632/oncotarget.20140

Figure 1. Progression-free survival in patients with advanced hepatocellular carcinoma and PVTT treated with combined apatinib and TACE.

Figure 1

The median progression-free survival was 8.1 months, with 6-month and 1-year rates of 73.3% and 22.9%, respectively.